This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
|Articles|February 1, 2005
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-02-01-2005
- Volume 17
- Issue 2
Process Considerations During API Development
Author(s)Mahesh Phansalkar, Nandita Shetgiri
This article looks at how to adopt a systematic and prospective approach in the API development process to achieve documented, controlled synthetic processes...
Advertisement
Articles in this issue
over 21 years ago
Monitoring Granulation Drying Using Near-Infrared Spectroscopyover 21 years ago
The Introduction of GMP for APIs in the European Unionover 21 years ago
Times They Are A-changingover 21 years ago
Documentary EvidenceAdvertisement
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains that developing a molecule requires a holistic view of its chemical, physical, and biological properties.
Advertisement
Advertisement